Chronic renal failure and HbA1c have a complex relationship that every clinician managing diabetes in kidney disease must understand. HbA1c is the standard marker for long-term glycaemic control, but in chronic kidney disease (CKD), physiological changes — including anaemia, uraemia, and altered red blood cell lifespan — can render results misleading, often producing falsely low readings. This article explains why HbA1c accuracy is compromised in renal impairment, which alternative monitoring tools are available, how NICE and NHS guidance applies, and how to manage blood glucose safely when kidney function is reduced.

How Chronic Renal Failure Affects HbA1c Accuracy

CKD causes anaemia and shortened red blood cell lifespan, leading to falsely low HbA1c results; uraemic carbamylation may also interfere with certain assay methods, though modern HPLC methods have reduced this effect.

Have any more questions about this? Message our pharmaceutical team to get more info →

HbA1c (glycated haemoglobin) is a widely used marker of long-term blood glucose control, reflecting average blood sugar levels over approximately two to three months. It works by measuring the proportion of haemoglobin that has become glycated — that is, chemically bonded to glucose — in circulating red blood cells. In healthy individuals, this provides a reliable snapshot of glycaemic management over time.

In chronic renal failure (also referred to as chronic kidney disease, or CKD), several physiological changes directly interfere with this measurement. One of the most significant is uraemia — the accumulation of urea and other waste products in the blood as kidney function declines. Uraemic compounds can cause carbamylation of haemoglobin, a chemical modification that may interfere with certain HbA1c assay methods. It is important to note that many modern high-performance liquid chromatography (HPLC) methods have been refined to minimise this interference; the degree of impact therefore depends on the specific assay used, and clinicians should consult their local laboratory for details of the method employed.

Additionally, patients with advanced CKD frequently develop anaemia, often due to reduced erythropoietin production by the damaged kidneys. This leads to a shortened red blood cell lifespan — variably reported as approximately 40–70 days compared with the normal 90–120 days, though the extent varies between individuals. Because HbA1c reflects glycation over the lifespan of red blood cells, a shorter lifespan means less time for glycation to accumulate, resulting in a falsely low HbA1c that does not accurately reflect true glucose exposure. This is a clinically important distinction, as it may lead clinicians to underestimate the degree of hyperglycaemia.

In patients receiving dialysis, the metabolic environment is further altered — haemodilution, use of erythropoiesis-stimulating agents (ESAs), and ongoing haemolysis can make HbA1c results particularly unreliable or even uninterpretable. In such cases, alternative monitoring approaches are generally preferred (see below).

Why HbA1c May Be Unreliable in Kidney Disease

ESA therapy, blood transfusions, haemoglobin variants, and assay-specific interferences all compound HbA1c unreliability in CKD, making results particularly untrustworthy at eGFR below 30 mL/min/1.73m².

Beyond anaemia and uraemia, several additional factors compound the unreliability of HbA1c in the context of chronic renal failure. Patients with CKD who are receiving ESAs or iron supplementation to treat renal anaemia may experience increased red blood cell turnover, further shortening the average red cell lifespan and artificially suppressing HbA1c values.

Patients who have received blood transfusions — not uncommon in advanced CKD — will have a proportion of donor red blood cells in circulation. This makes HbA1c results unreliable for approximately three months following a transfusion; the direction of bias is unpredictable and should not be assumed to be consistently low or high.

The type of laboratory assay used to measure HbA1c also matters. HPLC and immunoassay methods can respond differently to carbamylated haemoglobin and haemoglobin variants. Some assays may report spuriously high values in the presence of carbamylated haemoglobin, while others are less affected. Clinicians are encouraged to contact their local laboratory to understand which method is in use and whether any known interferences apply to their patient's results.

It is also worth noting that haemoglobin variants such as HbS or HbC — which are more prevalent in certain ethnic groups within the UK's diverse population — can independently affect HbA1c accuracy, regardless of renal function. When multiple confounding factors are present simultaneously, as is common in advanced CKD, the cumulative effect on HbA1c reliability becomes substantial. Clinicians should therefore interpret HbA1c results in CKD with considerable caution, particularly in stages 4 and 5 (eGFR below 30 mL/min/1.73m²).

Alternative Glycaemic Monitoring in Renal Impairment

Fructosamine and glycated albumin reflect shorter-term glucose control without red cell interference, but are limited by hypoalbuminaemia; CGM provides real-time glucose data and is increasingly preferred in CKD.

Given the limitations of HbA1c in CKD, alternative markers of glycaemic control have gained increasing clinical relevance. Two of the most commonly considered alternatives are fructosamine and glycated albumin.

• Fructosamine reflects average blood glucose over approximately two to three weeks, corresponding to the lifespan of serum proteins rather than red blood cells. It is therefore unaffected by anaemia or altered red cell survival. However, it can be significantly influenced by changes in serum albumin levels — which are frequently low in CKD patients due to protein loss, nephrotic-range proteinuria, malnutrition, or inflammation — potentially limiting its reliability. It may also be affected by thyroid and liver disease, and its performance in patients on dialysis is uncertain. Fructosamine is not recommended for the diagnosis of diabetes.

• Glycated albumin similarly reflects shorter-term glycaemic control (approximately two to four weeks) and may offer advantages over fructosamine in some CKD populations. However, it shares similar limitations in the context of hypoalbuminaemia, nephrotic syndrome, and dialysis, and is not yet widely available in routine NHS practice. It is also not suitable for diagnosing diabetes.

Continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG) using fingerprick testing are increasingly important tools in this population. Real-time CGM (rtCGM) and intermittently scanned CGM (isCGM) devices provide real-time glucose data and time-in-range metrics, offering a more nuanced picture of glycaemic variability than any single blood test. Multiple devices are now available on the NHS. In terms of NICE eligibility: all adults with type 1 diabetes should be offered CGM (NICE NG17); in type 2 diabetes, rtCGM or isCGM should be offered to those on insulin who meet defined criteria, including those experiencing recurrent hypoglycaemia or requiring frequent self-monitoring (NICE NG28). These technologies are particularly valuable in patients where HbA1c is known to be unreliable.

Ultimately, no single alternative fully replaces HbA1c, and clinical decision-making in CKD often requires a combination of approaches — integrating laboratory markers with patient-reported symptoms, glucose diary data, and clinical judgement.

NICE and NHS Guidance on Diabetes Monitoring in CKD

NICE NG28 and NG203 recommend interpreting HbA1c with caution in CKD and support individualised targets, with CGM offered to eligible patients and less stringent HbA1c goals in advanced disease.

NICE provides specific guidance relevant to the intersection of diabetes and chronic kidney disease. NICE guideline NG28 (Type 2 diabetes in adults) and NICE guideline NG203 (Chronic kidney disease: assessment and management) both acknowledge the complexity of glycaemic monitoring in patients with renal impairment. NICE recommends that HbA1c should be interpreted with caution in people with CKD, particularly those with anaemia or who are receiving treatments that affect red blood cell lifespan.

For patients with type 1 or type 2 diabetes and CKD, NICE supports the use of rtCGM or isCGM as part of an individualised monitoring strategy, subject to the eligibility criteria outlined in NG17 and NG28 respectively. NHS England has also committed to expanding access to CGM for people with diabetes, recognising that traditional monitoring methods may be insufficient for complex patients.

In terms of glycaemic targets, NICE advises that HbA1c targets should be individualised in people with CKD. As a general guide:

• An HbA1c target of 48 mmol/mol (6.5%) is appropriate for most adults with type 2 diabetes managed without agents that cause hypoglycaemia.

• A target of 53 mmol/mol (7.0%) is recommended for those using insulin or other agents associated with hypoglycaemia risk.

• In people with advanced CKD, significant comorbidities, or limited life expectancy, less stringent targets may be clinically justified, taking into account the heightened risk of hypoglycaemia due to reduced renal gluconeogenesis and altered drug clearance.

NICE NG203 also provides guidance on monitoring frequency and referral thresholds based on eGFR category, albuminuria (ACR), and estimated risk of kidney failure using the Kidney Failure Risk Equation (KFRE). The MHRA has issued guidance on the use of specific antidiabetic agents in renal impairment, including dose adjustments and contraindications — all of which have implications for glycaemic management and monitoring strategies in this population.

Managing Blood Sugar Safely With Reduced Kidney Function

Metformin is contraindicated below eGFR 30, insulin requirements fall as CKD advances, and SGLT-2 inhibitors have agent-specific thresholds; all antidiabetic regimens require regular review as kidney function declines.

Safe glycaemic management in chronic renal failure requires careful consideration of both the choice of antidiabetic medication and the monitoring approach. Several commonly used diabetes medicines require dose adjustment or cessation as kidney function declines:

• Metformin: generally considered safe in CKD stages 1–3a (eGFR ≥45 mL/min/1.73m²). In stage 3b (eGFR 30–44 mL/min/1.73m²), metformin should not be initiated; if already prescribed, continuation requires careful assessment of individual benefit versus risk, with a reduced maximum dose (typically no more than 1 g/day) and more frequent renal monitoring. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m² due to the risk of lactic acidosis. It should also be withheld temporarily during acute illness, dehydration, or before procedures involving iodinated contrast media ('sick-day rules'), and restarted only once renal function has been confirmed to be stable.

• Sulfonylureas (e.g., gliclazide): carry an increased risk of hypoglycaemia in CKD due to accumulation of active metabolites. Shorter-acting agents are generally preferred; doses should be reviewed regularly as eGFR declines.

• SGLT-2 inhibitors (e.g., dapagliflozin, empagliflozin): have reduced glycaemic efficacy at lower eGFR levels. Initiation and continuation thresholds vary by agent and indication — some are now licensed at lower eGFR thresholds specifically for their cardiorenal protective effects in CKD and heart failure, independent of glucose lowering. These agents are contraindicated in patients on dialysis. Patients should be counselled on sick-day rules and the risk of diabetic ketoacidosis (DKA), including euglycaemic DKA.

• GLP-1 receptor agonists: agent-specific renal considerations apply. Semaglutide and liraglutide generally require no routine dose adjustment in mild-to-moderate CKD. Exenatide is contraindicated when eGFR falls below 30 mL/min/1.73m². Caution is advised across this class in advanced disease due to gastrointestinal side effects and associated dehydration risk.

• Insulin: requirements often fall as eGFR declines, due to reduced renal insulin clearance. Doses should be reviewed proactively to reduce the risk of hypoglycaemia, particularly in CKD stages 4 and 5.

Patients should be encouraged to monitor for symptoms of hypoglycaemia — including shakiness, sweating, confusion, and palpitations — and to understand that these episodes may be more frequent and severe in the context of renal impairment. Dietary advice from a renal dietitian can also play an important role in stabilising blood glucose while managing the dietary restrictions often required in CKD, such as limiting potassium and phosphate intake.

If you or a patient experiences a suspected side effect from any diabetes medicine, this should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Healthcare professionals and patients can both submit reports.

When to Seek a Specialist Review for Glycaemic Control

Referral to a joint diabetes–renal clinic is recommended at CKD stage 4 or 5, or earlier if there is rapid eGFR decline, recurrent hypoglycaemia, or discrepancy between HbA1c and glucose monitoring data.

Patients with both diabetes and chronic renal failure should be under regular review by their GP and, in many cases, a specialist team. However, certain clinical situations warrant prompt escalation or referral:

• Unexplained discrepancy between HbA1c results and home glucose readings or CGM data, which may indicate that HbA1c is no longer a reliable monitoring tool

• Recurrent or severe hypoglycaemia, particularly if associated with loss of consciousness, seizure, or requiring third-party assistance

• Rapidly declining kidney function, defined by NICE NG203 as a sustained decrease in eGFR of 25% or more with a change in GFR category within 12 months, or a sustained decrease of 15 mL/min/1.73m² or more per year — either of which may necessitate urgent medication review

• A 5-year kidney failure risk of 5% or more as estimated by the Kidney Failure Risk Equation (KFRE), or an ACR of 70 mg/mmol or above (unless clearly attributable to a urinary tract infection), or an ACR above 30 mg/mmol with haematuria — all of which are NICE NG203 thresholds for nephrology referral

• Poorly controlled blood glucose despite optimised oral therapy, suggesting a need for insulin initiation or specialist input

• Progression to CKD stage 4 or 5, at which point referral to a joint diabetes–renal clinic (bringing together diabetologists, nephrologists, specialist nurses, and dietitians) is strongly recommended

In the UK, many NHS trusts operate dedicated joint renal-diabetes clinics that provide coordinated care for this complex patient group. Patients on dialysis or approaching the need for renal replacement therapy require particularly close glycaemic oversight, as the metabolic environment changes significantly with dialysis.

If you are a patient with diabetes and CKD and have concerns about your blood sugar control, blood test results, or medication, contact your GP practice in the first instance. Do not adjust insulin or other diabetes medicines without professional guidance, as changes in kidney function can alter drug metabolism rapidly and unpredictably.

Frequently Asked Questions